Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A

Rheumatology

Volumn 45, Issue 1, 2006, Pages 31-37

  Nowlan, M L ^a   Drewe, E ^a   Bulsara, H ^a   Esposito, N ^a   Robins, R A ^a   Tighe, P J ^a   Powell, R J ^a   Todd, Ian ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Etanercept; Pro inflammatory cytokines; TNF receptor; TRAPS

Indexed keywords

C REACTIVE PROTEIN; CYSTEINE; CYTOKINE; ETANERCEPT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN P70; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TYROSINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG MECHANISM; FAMILY STUDY; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN STABILITY; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; CYTOKINES; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MUTATION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SYNDROME;

EID: 29844442446     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei090     Document Type: Article

References (32)

1. McDermott M, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
2. McDermott E, Powell R. Circulating cytokine concentrations in familial Hibernian fever. In: Sohar E, Gafni J, Pras M, eds. Familial Mediterranean fever, 1st International Conference; 1997; Jerusalem, Israel. Tel Aviv: Freund Publishing House, 1997:189-2.
3. Drewe E, Huggins ML, Morgan AG, Cassidy MJD, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004; 43:1405-8.
4. Drenth J, van Deuren M, van der Ven-Jongerkrijg J, Schalkwijk C, van der Meer J. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995;85:3586-93.
5. Gang N, Drenth J, Langevitz P et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 1999;26:890-7.
6. Akcan Y, Bayraktar Y, Arslan S, Van Thiel DH, Zerrin BC, Yildiz O. The importance of serial measurements of cytokine levels for the evaluation of their role in pathogenesis in familial Mediterranean fever. Eur J Med Res 2003;8:304-6.
7. Bagci S, Toy B, Tuzun A et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 2004;23:333-7.
8. Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol 2003;22:99-101.
9. Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol 1999;26:1983-6.
10. Aypar E, Ozen S, Okur H, Kutluk T, Besbas N, Bakkalogu A. Thl polarization in familial Mediterranean fever. J Rheumatol 2003; 30:2011-3.
11. Koklu S, Ozturk MA, Balci M, Yuksel O, Ertenli I, Kiraz S. Interferon-gamma levels in familial Mediterranean fever. Joint Bone Spine 2005;72:38-40.
12. Galon J, Aksentijevich I, McDermott M, O'Shea J, Kastner D. TNFRSR1 A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000;12:479-86.
13. Todd I, Radford PM, Draper-Morgan KA et al. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004;113:65-79.
14. Huggins ML, Radford PM, McIntosh RS et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor associated periodic syndrome (TRAPS): Differences between cell types. Arthritis Rheum 2004;50:2651-9.
15. Tilg H, Trehu E, Atkins M, Dinarello C, Mier J. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-8.
16. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
17. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
18. Hull K, Wong K, Wood G, Chu W-S, Kastner D. Monocytic fasciitis: A newly recognized clinical feature of TNF-receptor dysfunction. Arthritis Rheum 2002;46:2189-94.
19. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004; 135:64-73.
20. Williamson L, Hull D, Mehta R, Reeves W, Robinson B, Toghill P. Familial Hibernian fever. Q J Med 1982;51:469-80.
21. Hogan M, Vogel S. Measurement of tumor necrosis factor-α and β. In: Coligan J, ed. Current protocols in immunology. New York: Wiley & Sons, 2000:6.10.1-6.10.5.
22. Simon A, Bodar EJ, van der Hilst JC et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med 2004; 117:208-10.
23. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients. Rheumatology 2003; 42:235-9.
24. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:FC; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNF alpha levels during treatment. Leuk Res 2003;27:375-80.
25. Eason JD, Pascual M, Wee S et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61:224-8.
26. Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
27. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
28. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
29. Evans T, Moyes D, Carpenter A et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9.
30. Trikha M, Corringham R, Klein B, Rossi J. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
31. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
32. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.